TELO Q3 2025 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

TELOTelomir Pharmaceuticals, Inc. Common Stock

$46M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$1M

Net Income

-$1M

EPS (Diluted)

$-0.03

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$927,265

Free Cash Flow

-$927,260

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$7M

Total Liabilities

$422,807

Stockholders' Equity

$7M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$1M	-$6M	+80.9%
Net Income	-$1M	-$6M	+81.6%